Arcturus Therapeutics Holdings Inc. (ARCT)

24,35 -0,10 (-0,41%) Börsenschluss: 04:00PM EDT

Arcturus Therapeutics Holdings Inc.

10628 Science Center Drive
Suite 250
San Diego, CA 92121
United States
858 900 2660
https://arcturusrx.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 180

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Joseph E. Payne M.Sc.	Founder, President, CEO & Director	906,5k	N/A	1972
Dr. Padmanabh Chivukula Ph.D.	Founder, Chief Scientific Officer, COO & Secretary	687,5k	N/A	1979
Mr. Andrew H. Sassine MBA	CFO & Director	687,5k	N/A	1964
Mr. Lance Kurata	Chief Legal Officer	600k	N/A	N/A
Ms. Neda Safarzadeh	Vice President and Head of IR/PR & Marketing	N/A	N/A	N/A
Ms. Natash O. Bowman	Chief Human Resources Officer	N/A	N/A	N/A
Mr. Kevin T. Skol	Chief Business Officer	N/A	N/A	N/A
Dr. Juergen Froehlich FCPh, M.D., MBA	Chief Medical Officer	N/A	N/A	1956
Dr. Igor Smolenov M.D., Ph.D.	Chief Development Officer	N/A	N/A	N/A
Ms. Roberta Duncan	Chief Strategy Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Corporate Governance

Arcturus Therapeutics Holdings Inc.s ISS Governance QualityScore, Stand 29. Juni 2024, lautet 8. Die grundlegenden Scores sind Audit: 9, Vorstand: 4, Shareholderrechte: 6, Kompensation: 10.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.